by Ryan Michalek | Jul 22, 2022 | Press Releases
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 – (GLOBE NEWSWIRE) – Heat Biologics,...
by Ryan Michalek | Jul 22, 2022 | Press Releases
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by...
by Admin | Jul 14, 2022 | Press Releases
ELUSYS THERAPEUTICS RECEIVES HEALTH CANADA APPROVAL FOR ANTHIM® FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, AUGUST 12, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for...
by Admin | Jul 14, 2022 | Press Releases
OBILTOXAXIMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF INHALATION ANTHRAX European Commission Decision Anticipated in November 2020 PARSIPPANY, NJ, OCTOBER 8, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal...
by Admin | Jul 14, 2022 | Press Releases
OBILTOXAXIMAB RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, DECEMBER 2, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company’s...
by Admin | Jul 14, 2022 | Press Releases
ELUSYS THERAPEUTICS FINALIZES HHS CONTRACT TO DELIVER ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first...
